What is Exmoor?
Exmoor operates as a specialized technical and strategic consultancy firm, providing critical expertise across the biopharmaceutical, secondary pharmaceutical, and cell and gene therapy landscapes. The company distinguishes itself by offering end-to-end support, beginning with the development of business cases and concept designs for capital projects, and extending through to the complex requirements of GMP biomanufacturing. By integrating programme management, process design, and rigorous GMP compliance, Exmoor serves as a vital partner for organizations navigating the transition from initial facility planning to full-scale beneficial operation and licensing. Its market position is defined by a unique blend of technical precision and strategic foresight, enabling clients to navigate the regulatory and operational hurdles inherent in advanced medicine production.
How much funding has Exmoor raised?
Exmoor has raised a total of $35M across 1 funding round:
Series A
$35M
Series A (2023): $35M with participation from MVM Partners
Key Investors in Exmoor
MVM Partners
MVM Partners LLP is a seasoned investment firm specializing in innovative healthcare companies, with a focus on medical technology, pharmaceuticals, and digital health. Based in Boston, London, and San Francisco, the firm partners with management teams to drive growth and address significant unmet needs in global healthcare markets.
What's next for Exmoor?
With this major enterprise-level funding, Exmoor is poised to scale its service offerings and deepen its technical bench strength. The strategic allocation of this capital will likely focus on enhancing the firm's capacity to manage increasingly complex biomanufacturing projects, potentially expanding its reach into new geographic markets or specialized therapeutic areas. As the demand for robust cell and gene therapy infrastructure continues to rise, Exmoor's ability to provide comprehensive GMP compliance and facility design will be a key driver of its long-term growth. The firm is expected to leverage this investment to solidify its reputation as a premier consultancy, ensuring that its clients remain at the forefront of pharmaceutical innovation while maintaining the highest standards of operational excellence.
See full Exmoor company page
